Gilead Sciences, Bristol-Myers Squibb, Gilead Sciences, and Teva Pharmaceuticals were named in a lawsuit filed by New Mexico Attorney General Hector Balderas for violating the state’s Antitrust Act and Unfair Practices Act, reported Bloomberg.
The lawsuit, filed in the First Judicial District Court of New Mexico, stems from the development, marketing, and manufacturing of several antiretroviral medications used in the prevention and treatment of the HIV virus
Lawsuit alleges that the defendants “engaged in coordinated schemes and anticompetitive agreements to suppress the entry of cheaper generic versions of each drug into the market, and to delay the development of safer drugs.
A press release from the attorney general explains that the lawsuit alleges that the defendants engaged in coordinated schemes and anti-competitive agreements in order to repress the entry of cheaper generic versions of each drug into the market and to hinder the development of safer, more effective treatment drugs as a means to maintain a grip on the market for antiretroviral treatment. The lawsuit claims these actions resulted in inflated prices for the lifesaving drugs as well as hundreds of millions of dollars in anticompetitive profits to the defendants.
“Putting profits over the critical needs of New Mexican patients and risking their health and safety is unacceptable,” said Attorney General Balderas in a press release. “My office will hold anyone accountable who takes advantage of or harms our families.”
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Chamber of Commerce Sues to Overturn FTC Non-Compete Ban
Apr 24, 2024 by
CPI
FTC Chief Warns of Healthcare Price Fixing Risks Amid Tech Advancements
Apr 24, 2024 by
CPI
Amazon’s Investment in Anthropic Faces Antitrust Scrutiny
Apr 24, 2024 by
CPI
Italian Antitrust Authority Fines Amazon €10 Million for Unfair Trade Practices
Apr 24, 2024 by
CPI
Tuta Mail Raises Alarm Over Google Search Ranking Plunge Amidst DMA Rollout
Apr 24, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI